Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Operating Leases: 2023-2024

  • BioLineRx's Operating Leases fell 11.83% to $1.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.6 million, marking a year-over-year decrease of 11.83%. This contributed to the annual value of $1.6 million for FY2024, which is 11.83% down from last year.
  • According to the latest figures from Q4 2024, BioLineRx's Operating Leases is $1.6 million, which was down 11.83% from $1.8 million recorded in Q4 2023.
  • In the past 5 years, BioLineRx's Operating Leases ranged from a high of $1.8 million in Q4 2023 and a low of $1.6 million during Q4 2024.
  • Moreover, its 2-year median value for Operating Leases was $1.7 million (2023), whereas its average is $1.7 million.
  • Data for BioLineRx's Operating Leases shows a maximum YoY decreased of 11.83% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows BioLineRx's Operating Leases stood at $1.8 million in 2023, then decreased by 11.83% to $1.6 million in 2024.